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Simple Summary: Pancreatic cancer is a leading cause of cancer death worldwide. In the majority of
patients, cancers are diagnosed at advanced stages of disease and are resistant to current treatments.
Therefore, more effective and less toxic therapeutic agents are urgently needed. Monoclonal antibody
(mAb)-based technology is an important tool in the discovery of novel therapeutic targets and
development of novel therapeutic agents including antibody-based drugs. In this article, we review
the therapeutic potential of monoclonal antibody-based agents when used as single agents or in
combination with other treatments in pancreatic cancer, factors contributing to the poor response to
therapy and emerging opportunities for more effective treatment with antibody-based agents.
Abstract: Pancreatic cancer remains as one of the most aggressive cancer types. In the absence of
reliable biomarkers for its early detection and more effective therapeutic interventions, pancreatic
cancer is projected to become the second leading cause of cancer death in the Western world in the
next decade. Therefore, it is essential to discover novel therapeutic targets and to develop more
effective and pancreatic cancer-specific therapeutic agents. To date, 45 monoclonal antibodies (mAbs)
have been approved for the treatment of patients with a wide range of cancers; however, none
has yet been approved for pancreatic cancer. In this comprehensive review, we discuss the FDA
approved anticancer mAb-based drugs, the results of preclinical studies and clinical trials with
mAbs in pancreatic cancer and the factors contributing to the poor response to antibody therapy (e.g.
tumour heterogeneity, desmoplastic stroma). MAb technology is an excellent tool for studying the
complex biology of pancreatic cancer, to discover novel therapeutic targets and to develop various
forms of antibody-based therapeutic agents and companion diagnostic tests for the selection of
patients who are more likely to benefit from such therapy. These should result in the approval and
routine use of antibody-based agents for the treatment of pancreatic cancer patients in the future.
Keywords: pancreatic cancer; monoclonal antibodies; mAbs; targeted therapy; target antigens
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common and aggressive
cancer types, with a five-year survival rate of only 2–9% [1]. Worldwide, there were an
estimated 458,918 new cases of pancreatic cancer and 432,242 deaths in 2018 [2,3]. In the
absence of reliable biomarkers for use in the screening and early detection of pancreatic
cancer, and more effective and less toxic therapeutic agents, it has been projected that
pancreatic cancer will not only rise in incidence but also will take over breast, prostate and
colorectal cancers and become the second leading cause of cancer death in the Western
world by 2030 [1,4,5].
Treatment of patients with pancreatic cancer involves surgery, chemotherapy and
radiotherapy. Although surgery is the only curative treatment, around 80% of patients are
diagnosed at late stages of the disease and are not eligible for surgical resection. Adjuvant
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treatment with chemotherapy is beneficial given the high rate of locoregional relapse after
surgery alone. Gemcitabine-based therapy was traditionally the mainstay for treatment of
pancreatic cancer [6]. However, the results of the recently published ESPAC-4 trial showed
that the combination of gemcitabine plus capecitabine increased median overall survival
compared to gemcitabine alone (28.0 vs 25.5 months) with an acceptable toxicity profile,
and an estimated 5-year survival of 28.8% for the combination group compared to 16.3%
with gemcitabine monotherapy, making this combination the new standard of care in the
adjuvant setting [7]. Treatment for borderline resectable or locally advanced unresectable
tumours seems to yield better results with chemotherapy (e.g., FOLFIRINOX) rather than
chemoradiotherapy, although more robust evidence from trials is needed [8].
Patients with metastatic disease are treated with either FOLFIRINOX or gemcitabine
plus nab-paclitaxel as first-line in patients with good performance status [9,10]. Erlotinib
was approved by the FDA for use in metastatic pancreatic cancer patients based on a study
that showed a modest improvement in median survival in patients who received erlotinib
plus gemcitabine compared to gemcitabine alone (6.4 vs 5.9 months) but the clinical
relevance is controversial [11]. The combination of liposomal irinotecan, fluorouracil and
folinic acid (NAPOLI-1 regimen) is the only currently approved second-line chemotherapy
for patients with metastatic pancreatic cancer based on a phase 3 trial that showed median
overall survival of 6.1 months for the triple combination compared to 4.2 months in patients
receiving fluorouracil and folinic acid [12]. Therefore, it is essential to discover novel targets
and to develop more effective, less toxic and pancreatic cancer specific therapeutic agents
for the long-term benefit of patients with pancreatic cancer.
The advent of hybridoma technology by Köhler and Milstein in 1975, which allows
the production of unlimited quantity of an antibody against any target antigen, has rev-
olutionised many areas of biomedical research and medicine [13]. Further technological
advances in genetic engineering allowed the production of less immunogenic and more
effective types of mAbs (e.g., chimeric, humanised, fully human mAbs, antibody fragments
and bispecific antibodies) for use in the treatment of patients with a range of diseases includ-
ing cancer [14–18]. Indeed, mAb-based therapy is currently one of the two major types of
targeted therapy and an attractive therapeutic alternative for the treatment of patients with
a wide range of cancers. In this article, we provide a comprehensive review of monoclonal
antibody-based agents that have been approved for the treatment of human cancers and
the current state of preclinical and clinical studies with monoclonal antibody-based agents
in pancreatic cancer. We shall also highlight some of the contributing factors for the poor
response to therapy with mAbs, and emerging opportunities for more effective treatment
of pancreatic cancer with antibody-based agents in combination with other treatments.
2. Therapeutic Antibodies Approved in Cancer
Over the past few decades, monoclonal antibody-based agents have been approved
and used routinely in the treatment of a wide range of human diseases including cancer,
infectious, autoimmune and metabolic diseases. Monoclonal antibody-based drugs can
be developed by a variety of approaches such as hybridoma technology, phage display
technology, the use of transgenic mouse or the single B-cell technique [17,19,20].
Depending on the target antigen and the antibody format, monoclonal antibody-
based drugs can produce their anti-tumour activity by several mechanisms (Figure 1).
Some mAbs are directed against growth factor receptors with high levels of expression
in tumours cells and inhibit tumour growth by blocking the binding of growth factor
to its receptor (e.g., anti-EGFR mAbs cetuximab and panitumumab), or by inhibiting
receptor dimerization (e.g., anti-HER-2 mAb pertuzumab), consequently inhibiting the
downstream cell signalling pathways. In contrast, other antibodies halt tumour growth
by inhibiting angiogenesis (e.g., anti-VEGF blocking mAb bevacizumab), stimulating
apoptosis (e.g., anti-CD20 mAb rituximab) or delivering lethal doses of radioisotopes
(e.g., ibritumomab tiuxetan), or toxins to tumour sites (e.g., brentuximab vedotin, an anti-
CD30 mAb conjugated to anti-microtubule agent monomethyl auristatin E). Other mAbs
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induce tumour killing by immune-mediated antibody-dependent cellular cytotoxicity
(ADCC)/complement-dependent cytotoxicity (CDC, e.g., rituximab, trastuzumab) and im-
mune checkpoint inhibition through targeting of PD-1/PD-L1 and CTLA-4 (e.g., nivolumab,
pembrolizumab, atezolizumab, ipilimumab). Finally, other therapeutic mAbs are used
as component of CAR-T cells, or as bispecific antibodies that induce tumour killing by
simultaneous targeting of two different antigens on tumour cells, or bispecific immune
cell engager by targeting one antigen on tumour cells and another antigen on T cells
(e.g., catumaxomab, blinatumomab, Figure 1).
Figure 1. Mechanisms of action of monoclonal antibody-based products. (A) Targeting growth factor receptors, blocking the
binding of an activating ligand and inhibiting receptor homo- and heterodimerization; (B) Targeting of tumour vasculature
receptor or its ligands inhibiting angiogenesis; (C) Induction of apoptosis by recruitment of immune effector cells (ADCC)
or activation of the complement cascade (CDC), and the use of antibody-based molecules to engineer T lymphocytes (CAR
T cells); (D) Immune checkpoint inhibition by blockade of the PD-1/PD-L1 axis or CTLA-4 inhibitory receptors, increasing
cytotoxic T cell activity; (E) Simultaneous targeting of two antigens, one on tumour cells and one on effector T cells, by
using bispecific antibodies (BITE, bispecific T-cell enhancing); and (F) Delivery of payloads such as toxins and radioisotopes
to tumour cells. Created with BioRender.com (accessed on 17 March 2021).
To date, 45 mAbs have been approved in the USA and/or the European Union (EU) for
the treatment of patients with a wide range of cancers (Table 1). In particular, there has been
a great deal of research interest in this area in recent years and a growing number of mAb
approvals for different indications. Indeed, with the exception of checkpoint inhibitors,
nearly half of the approved therapeutic antibodies are directed against one of the following
six target antigens: CD19, CD20, the two members of the human epidermal growth factor
receptor (HER) family namely EGFR and HER-2, VEGF and VEGFR (Table 1). Interestingly,
several immune checkpoint inhibitors such as anti-CTLA-4 mAb ipilumumab, anti-PD-1
mAbs pembrolizumab and nivolumab, and anti-PD-L1 mAbs avelumab and durvalumab
have been approved for a wide range of cancer types. Moreover, additional mAbs have
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been approved outside the USA and EU for treatment of various cancer types including
nimotuzumab (in head and neck cancer, nasopharyngeal cancer and glioma) and vivatuxin
(in lung cancer) [16].
Table 1. Monoclonal antibodies approved in the U.S. and/or European Union for cancer treatment.
MAb Generic Name
(Trade Name)
Target Antigen/Isotype Cancer Type Indication
Date of
Approval
Rituximab (Rituxan®) CD20/Chimeric IgG1
B-cell lymphoma, NHL 1997
Diffuse large B-cell, CD20+, NHL 2006
CLL 2010
Previously untreated follicular, CD20+, B-cell NHL 2011
Trastuzumab (Herceptin®) HER-2/Humanised IgG1
Metastatic breast cancer 1998
Early-stage breast cancer 2006







Newly diagnosed, relapsed or refractory CD33+ AML 2017
Alemtuzumab
(Campath®)











Cetuximab (Erbitux®) EGFR/Chimeric IgG1
Metastatic CRC 2004
Locally or regionally advanced HNSCC or recurrent
or metastatic HNSCC
2006
Recurrent locoregional disease and/or metastatic
HNSCC (first-line)
2011
K-ras wild-type, EGFR-expressing metastatic CRC
(first-line)
2012
Bevacizumab (Avastin®) VEGF/Humanised IgG1
Metastatic CRC 2004
Locally advanced, metastatic or recurrent NSCLC 2006




Persistent, recurrent or metastatic cervical cancer 2014
Platinum-resistant, recurrent epithelial ovarian,
fallopian tube, or primary peritoneal cancer
2014
Stage III or IV epithelial ovarian, fallopian tube, or
primary peritoneal cancer after initial
surgical resection
2018
Panitumumab (Vectibix®) EGFR/Human IgG2 Metastatic CRC 2006
Ofatumumab (Arzerra®) CD20/Human IgG1
CLL 2009
CLL (previously untreated) 2014






Malignant ascites (in Europe) 2009




Target Antigen/Isotype Cancer Type Indication
Date of
Approval
Ipilimumab (Yervoy®) CTLA-4/Human IgG1
Unresectable or metastatic melanoma 2011
Cutaneous melanoma with pathological involvement
of regional lymph nodes
2015
Intermediate or poor risk, previously untreated
advanced RCC (in combination with nivolumab)
2018








ALCL and HL 2011
cHL (as consolidation post-auto-HSCT) 2015
pcALCL or CD30-expressing MF 2017
Previously untreated stage III or IV cHL 2018
Previously untreated systemic ALCL or other
CD30-expressing peripheral T-cell lymphomas
2018
Pertuzumab (Perjecta®) HER-2/Humanised IgG1
HER-2 positive metastatic breast cancer 2012
HER-2 positive, locally advanced, inflammatory, or
early-stage breast cancer (in combination with
trastuzumab as neoadjuvant therapy)
2013
HER-2 positive early breast cancer at high risk
or recurrence
2017





HER-2 positive, metastatic breast cancer 2013
HER-2 positive breast cancer with residual
invasive disease
2019
Obinutuzumab (Gazyva®) CD20/Humanised IgG1
CLL (previously untreated) 2013
FL 2016

















Unresectable or metastatic melanoma and disease
progression following ipilimumab
2014









Locally advanced or metastatic urothelial carcinoma 2017
Unresectable or metastatic MSI-H or dMMR
solid tumours
2017
Recurrent locally advanced or metastatic gastric or
GEJ adenocarcinoma
2017
Recurrent or metastatic cervical cancer 2018
Refractory PMBCL 2018
First-line treatment metastatic non-squamous NSCLC 2018
First-line treatment metastatic squamous NSCLC 2018
HCC 2018











Recurrent locally advanced or metastatic Merkel
cell carcinoma
2018
Melanoma with involvement of lymph nodes
following complete resection
2019
First-line treatment stage III or metastatic NSCLC 2019
First-line treatment advanced RCC 2019




Advanced oesophageal squamous cell cancer 2019
Advanced endometrial carcinoma that is not MSI-H
or dMMR
2019
BCG-unresponsive, high-risk, non-muscle invasive
bladder cancer with carcinoma in situ with or without
papillary tumours
2020
Unresectable or metastatic tumour mutational
burden-high (TMB H) solid tumours
2020
Recurrent or metastatic CSCC not curable by surgery
or radiation
2020




Locally recurrent unresectable or metastatic TNBC






Philadelphia chromosome-negative R/R B-cell
precursor ALL
2014
R/R B-cell precursor ALL 2017
B-cell precursor ALL in first or second complete
remission with MRD >/= 0.1%
2018
Nivolumab (Opdivo®) PD-1 receptor/Human IgG4
Unresectable or metastatic melanoma 2014
BRAF V600 wild-type, unresectable or metastatic





Recurrent or metastatic HNSCC 2016
Locally advanced or metastatic urothelial carcinoma 2017
MSI-H or dMMR metastatic CRC 2017
HCC 2017
Melanoma with involvement of lymph nodes or
metastatic disease following complete resection
2017
Intermediate or poor risk, previously untreated
advanced RCC (in combination with ipilimumab)
2018
Metastatic SCLC 2018
HCC (in combination with ipilimumab) 2018
First-line treatment metastatic NSCLC whose tumours
express PD-L1 (in combination with ipilimumab)
2020




Unresectable malignant pleural mesothelioma
(first-line; in combination with ipilimumab)
2020
First-line treatment advanced renal cell carcinoma (in
combination with cabozantinib)
2021




Target Antigen/Isotype Cancer Type Indication
Date of
Approval





Newly diagnosed MM ineligible for autologous SCT 2019
Newly diagnosed MM eligible for autologous SCT 2019
Necitumumab
(Portrazza®)
EGFR/Human IgG1 Metastatic squamous NSCLC (first-line) 2015
Elotuzumab
(Empliciti®)
SLAMF7/Humanised IgG1 MM 2015
Atezolizumab (Tecentriq®) PD-L1/Humanised IgG1
Locally advanced or metastatic urothelial carcinoma 2016
Metastatic NSCLC 2016
First-line treatment metastatic non-squamous NSCLC 2018
Unresectable locally-advanced or metastatic TNBC 2019
Extensive-stage SCLC 2019
Unresectable or metastatic HCC (in combination
with bevacizumab)
2020





PDGFRα/Human IgG1 Metastatic soft-tissue sarcoma 2016
Avelumab (Bavencio®) PD-L1/Human IgG1
Metastatic Merkel cell carcinoma 2017
Locally advanced or metastatic urothelial carcinoma 2017
Advanced RCC 2019
Maintenance treatment in locally advanced or
metastatic urothelial carcinoma (UC)
2020
Durvalumab (Imfinzi®) PD-L1/Human IgG1
Locally advanced or metastatic urothelial carcinoma 2017









R/R B-cell precursor ALL 2017
Mogamulizumab
(Poteligeo®)











Metastatic CSCC or locally advanced CSCC who are
not candidates for curative surgery or
curative radiation
2018
Locally advanced and metastatic basal cell carcinoma 2021
First-line treatment of advanced NSCLC whose















Locally advanced or metastatic urothelial cancer 2019













Unresectable or metastatic HER2-positive
breast cancer
2019
Locally advanced or metastatic HER2-positive gastric
or GEJ adenocarcinoma
2021
























Naxitamab (Danyelza®) GD2/Humanised IgG1
R/R high-risk neuroblastoma in the bone or bone






Metastatic HER2-positive breast cancer 2020
ADC: antibody drug conjugate; ALCL: anaplastic large cell lymphoma; ALL: acute lymphoblastic leukaemia; AML: acute myeloid
leukaemia; auto-HSCT: autologous hematopoietic stem cell transplantation; BCG: Bacillus Calmette-Guerin; B-CLL: B-cell chronic
lymphocytic leukaemia; BCMA: B-cell maturation antigen; cHL: classical Hodgkin lymphoma; CLL: chronic lymphocytic leukaemia; CRC:
colorectal cancer; CSCC: cutaneous squamous cell carcinoma; CTLA-4: cytotoxic T lymphocyte antigen-4; DLBCL: diffuse large B-cell
lymphoma; dMMR: mismatch repair deficient; EGFR: epidermal growth factor receptor; EpCAM: epithelial cell adhesion molecule; FL:
follicular lymphoma; GBM: glioblastoma multiforme; GD2: surface disialoganglioside GD2; GEJ: gastroesophageal junction; GM-CSF:
granulocyte-macrophage colony-stimulating factor; HCC: hepatocellular carcinoma; HER-2: human epidermal growth factor receptor-2;
HNSCC: head and neck squamous cell carcinoma; MM: multiple myeloma; MMAE: monomethyl auristatin E; MRD: minimal residual
disease; MSI-H: microsatellite instability-high; NHL: non-Hodgkin lymphoma; NSCLC: non-small-cell lung cancer; pcALCL: primary
cutaneous anaplastic large cell lymphoma; PDGFRα: platelet-derived growth factor receptor alpha; PD-1: programmed death-1 receptor;
PD-L1: programmed death ligand-1; PMBCL: primary mediastinal large B-cell lymphoma; RANKL: receptor activator of nuclear factor-
kappa B ligand; RCC: renal cell carcinoma; R/R: relapsed or refractory; SCLC: small cell lung cancer; SCT: stem cell transplant; SLAMF7:
signalling lymphocytic activation molecule F7; TNBC: triple-negative breast cancer. VEGF: vascular endothelial growth factor; VEGFR-2:
vascular endothelial growth factor receptor 2. * withdrawn; Taken from: https://www.fda.gov/drugs/resources-information-approved-
drugs/hematologyoncology-cancer-approvals-safety-notifications. Updated as of 12 March 2021.
However, despite such advances, to date no antibody-based drugs have been approved
for the treatment of patients with pancreatic cancer [21]. Some of the contributing factors
are the harsh desmoplastic microenvironment of pancreatic cancer, the heterogeneous
nature of tumours and the lack of reliable predictive biomarkers and companion diagnostic
tests to select patients who are more likely to respond to such therapy [22–25]. In the
following sections, we discuss the results of preclinical studies and clinical trials with
antibody-based agents in pancreatic cancer. We will also highlight the importance of
antibody-based technology and other approaches in the discovery of cell surface antigens
with high levels of expression in pancreatic cancer (i.e., additional therapeutic targets) and
in the development of mAb-based targeted therapy for patients with pancreatic cancer.
3. Preclinical Studies
Over the past few decades, the therapeutic and diagnostic potential of monoclonal
antibodies against pancreatic cancer has been investigated both in vitro and in vivo and
the results are summarised in Table 2.
The results from cell proliferation assays in human pancreatic cancer cell lines, cell
line-based xenografts and patient-derived tumour xenografts have demonstrated antitu-
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mour activity either as single agents or in combination with cytotoxic drugs. The results
of in vitro studies have supported the therapeutic potential of mAbs targeting integrin
α3 [26], MUC4 [27], MUC1 [28], and MUC13 [29] when used alone or in combination with
cytotoxic drugs. Furthermore, mAbs targeting EGFR, TROP2 and α6β4 have been used
for radioimmunotherapy and have shown effective localisation of primary tumours and
metastatic sites in mouse models [30–32].
Moreover, in vivo, naked and conjugated versions of anti-tissue factor mAbs have
shown significant antitumour activity in mouse models [33–36]. Similarly, treatment with
mAbs targeting podocalyxin [37], HER2 [38], glypican-1 [39], cell surface plectin 1 [40],
galectin-9 [41], RON [42], BAG3 [43], CLDN18.2 [44], mesothelin [45], vimentin [46] and
doublecortin-like kinase 1 [47] inhibited the growth of pancreatic tumours in xenograft
models. On the other hand, mAbs have also been studied as platforms for cancer thera-
nostics (i.e., a combination of diagnostics and therapeutic) in several animal models [48].
An array of immunoconjugates with radiolabelled antibodies have been used for in vivo
imaging using antibody-based PET and SPECT techniques and the results of mAbs target-
ing CA19.9 and CD147 have shown promise in mouse models [49–51]. The main findings
are summarized in Table 3.
Table 2. Monoclonal antibodies against pancreatic cancer in preclinical studies for use as therapeutic tools.





Significantly inhibited tumour growth in an
orthotopic xenograft model, and extended







Orthotopic pancreatic tumours in mice treated
with h-RabMab1 were 60% smaller than











Reduced cell viability and cell motility, and
modulated the expression of EMT markers
(vimentin and E-cadherin) in pancreatic cancer
cells that endogenously express TM4SF5.
[52]
Panitumumab labelled
with 111In or 177Lu -
EGFR -
Radioimmunotherapy with panitumumab
labelled with Auger electron-emitting 111In or β
particle-emitting 177Lu inhibited the growth of
subcutaneous PANC-1 human pancreatic
cancer xenografts in mice.
[30]
PcMab-60 PODXL Soluble PODXL
Demonstrated antitumour activity in Mia
PaCa-2 xenograft mouse models.
[37]
7E IL-20 -
Prolongs survival and attenuates PD-L1
expression in a transgenic mouse and an
orthotopic pancreatic cancer model.
Combination of 7E and an anti-PD-1 mAb
increases efficacy in inhibiting tumour growth










Slow tumour growth compared to the control
groups and had significantly smaller tumour
volumes 1-day post-injection.
[35]
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Table 2. Cont.







Induces significant tumour growth inhibition
against GPC-1-positive pancreatic cell lines






Inhibits proliferation of Capan-2 pancreatic
cancer cells and increases migration of
CFPAC-1 and BxPC-3 cancer cells in vitro.
[26]
6E8 and E9 MUC4 MUC4beta domain
Decreased proliferation and migration of




lysate isolated from an
adenocarcinoma
developed by a mouse
that was transgenic for
human MUC1
TAB004 + Lip-MSA-IL-2 significantly improved
survival and slowed tumour growth compared
to controls in a human MUC1 transgenic mouse
model of pancreatic cancer.
[54]
TROP2-IR700 TROP2 -
Photoimmunotherapy with the humanised
anti-TROP2 mAb conjugated to the
photosensitizer IR700 significantly inhibits







Decreases tumour volume 5-fold in xenografts,
and induces complete tumour regression in




TAB004 treatment had minimal effect as single
agent on most of pancreatic cancer cell lines
except for Capan-2. However, when combined
with gemcitabine, paclitaxel, or 5-FU, it
significantly increased anti-tumour efficacy.
[28]
Anti-Gal-9 mAb Galectin-9 -
Induced significant reduction in tumour size in
orthotopic pancreatic cancer mouse models.
[41]
28H1 FAP -
The dual-labeled mAb (conjugated with either
DTPA for imaging studies or with DTPA and
the photosensitizer IRDye700DX for therapy
studies) targets pancreatic tumours in mice
with good signal-to-background ratios and




The RC68-based antibody-drug conjugates
induced death of EGFR-positive pancreatic




Inhibited the growth of pancreatic cancer






Significantly inhibits the growth of Mia PaCa-2
pancreatic cancer cell xenografts
[43]
Zolbetuximab CLDN18.2 -
Slow tumour growth, improve survival and
attenuate development of metastases in
xenograft models. Gemcitabine enhanced
zolbetuximab-induced ADCC.
[44]
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Table 2. Cont.
mAb Name Target Antigen Source/Immunogen Finding Ref.
1849-ICG conjugate TF -
A single dose of 1849-ICG conjugate
accompanied by NIR light exposure inhibited






Combined treatment using 90Y-labeled 059-053
with gemcitabine significantly suppressed
tumour growth and prolonged survival with
tolerable toxicity in a BxPC-3 xenograft mouse
model of refractory pancreatic cancer.
[57]
Amatuximab Mesothelin -
Supressed the development of peritoneal
metastases and exhibited synergistic killing in
combination with gemcitabine in a peritoneal
metastatic pancreatic cancer model.
[45]
Anti-hMUC1 antibody MUC1 rhMUC1-EC192 protein
Specifically targets MUC1-C pancreatic cancer
cells in vitro and in vivo and suppresses the







of a patient with
cervical carcinoma
Inhibits subcutaneous pancreatic cancer
xenografts models. The binding of the antibody







Inhibits migration and growth of pancreatic
cancer cells co-cultured with CAFs in
















A single dose of 90Y-ITGA6B4 inhibited tumour








The ADC induced potent antitumour activity in
both cell line– and patient-derived xenograft
models of pancreatic and prostate cancers.
Combination studies of ASG5ME and
nab-paclitaxel increased antitumour activity







Reduced tumour growth and metastasis and
led to regression of xenograft tumours in mice,







Induced almost complete response in mice
bearing Mia PaCa-2 tumours (high TfR
expression), but it had limited efficacy on
BxPC-3 tumours (low TfR expression).
[62]
BNC101 LRG5 -
BNC101 as single agent partially inhibited
tumour growth in AsPC1 and PANC-1
pancreatic cancer models, while when used in
combination with gemcitabine, it significantly
inhibited tumour growth in both models. In
contrast, BNC101 as monotherapy or in
combination with chemotherapy had no
antitumour activity in the LGR5 negative
BxPC3 xenograft tumours.
[63]
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Table 2. Cont.
mAb Name Target Antigen Source/Immunogen Finding Ref.
TCC56 MUC13 PAN2 cells
The ADC can be efficiently internalised and





Inhibited tumour growth and angiogenesis in
NOD/SCID mice bearing MIA PaCa-2-derived
pancreatic cancer xenografts.
[64]
ADCC: antibody-dependent cellular cytotoxicity; AGR2: anterior gradient 2; CAFs: cancer-associated fibroblasts; EGFR: Epidermal
growth factor receptor; GPC-1: glypican-1; ICG: indocyanine green; LGR5: leucine-rich repeat-containing G-protein coupled receptor 5;
MMAE: monomethyl auristatin E; MMAF: monomethyl auristatin F; MUC1: mucin 1; MUC5AC: mucin 5AC; PC: pancreatic cancer; NIR:
near-infrared photoimmunotherapeutic; PODXL: podocalyxin; TfR: transferrin; TF: tissue factor; TM4SF5: transmembrane 4 superfamily
member 5 protein; TROP2: tumour-associated calcium signal transducer 2.













sLea – KLH vaccine
PET imaging allows monitoring of tumour
radiobiological response in a BxPC-3 pancreatic












Immunodetects integrin α3 by IHC in tumour cell





Immunodetects CD26 by IHC in tumour cell pellets





Immunodetects CD109 by Western blot and IHC in




Demonstrated high binding affinity and






89Zr-059-053 highly accumulated in
CD147-expressing tumours and clearly visualised
subcutaneous and orthotopic xenografts.
[50]
CEACAM: carcinoembryonic antigen-related cell adhesion molecules; IHC: immunohistochemistry; MUC1: mucin 1; PET: positron
emission tomography.
4. Clinical Trials Evaluating the Diagnostic and Therapeutic Potential of Monoclonal
Antibodies in Pancreatic Cancer
As the results of some preclinical studies summarised in Table 2 were encouraging,
several monoclonal antibodies entered different stages of clinical trials in patients with
pancreatic cancer. Tables 4–6 summarise the results of phase I/II, phase III and ongoing
clinical trials with various antibody-based agents (the results of studies in Tables 4 and 5
are presented in chronological order with the most recent studies at the top of the tables).
In the following sections, the antigens targeted by these antibodies (Figure 2), the biological
significance of the antigens and the results of completed clinical trials with such antibodies
are discussed.
4.1. Clinical Trials with Antibodies Targeting Insulin-Like Growth Factor Receptor (IGF-IR)
Insulin-like growth factor (IGF) signalling activates intracellular pathways such as
PI3K (phosphatidyl inositol 3-kinase), Rac, AKT, and MAPK (mitogen-activated protein
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kinase), regulating the processes involved in cellular proliferation, differentiation and
apoptosis. IGF axis has been implicated in various cancer types including pancreatic,
breast and prostate cancer, melanoma and Ewing sarcoma and has been associated with
the development of resistance to other cancer treatments [68–70].
Figure 2. Antigens targeted by antibodies in patients with pancreatic cancer. Created with BioRender.
com (accessed on 17 March 2021).
Ganitumab (AMG 479) is a fully human IgG1 mAb that binds to the extracellular
domain of the type I insulin-like growth factor receptor (IGF-IR), interfering with the
binding of IGF-1 and IGF-2 ligands, thus inhibiting downstream signalling including
PI3K/Akt pathway and leading to inhibition of tumour cell proliferation and induction
of apoptosis [71,72]. In a phase 2 study, ganitumab in combination with gemcitabine
showed trend towards improved OS compared to gemcitabine alone in patients with
metastatic pancreatic cancer [73], although the GAMMA phase 3 trial failed to further
validate those results [74].
On the other hand, cixutumumab (IMC-A12), a fully human IgG1/λ mAb against
IGF-IR [75], was evaluated in combination with erlotinib and gemcitabine in a phase
1b/2 study in metastatic pancreatic cancer patients but did not demonstrate survival
benefit [76]. Furthermore, dalotuzumab (MK-0646), an IgG1 humanised mAb specific
to IGF-1R was evaluated in combination with gemcitabine in a phase 1/2 study that
demonstrated improved OS but not PFS compared to gemcitabine plus erlotinib [77].
Future trials are needed to evaluate the combination of dalotuzumab with standard of care
gemcitabine/nab-paclitaxel and FOLFIRINOX.
4.2. Clinical Trials with Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies
HER family members (which includes EGFR, HER2, HER3 and HER4) are activated
by its ligands in an autocrine, paracrine or juxtacrine manner, which involves conforma-
tional changes leading to homo- or heterodimerisation of HER members and activation
of downstream signalling pathways [70,78]. HER family plays a major role in cancer pro-
gression and development, regulating several hallmarks of cancer and therefore becoming
an attractive therapeutic target [78]. EGFR (also known as ErbB1/HER1) is commonly
Cancers 2021, 13, 1781 14 of 38
upregulated in several cancer types including pancreatic cancer, and thus EGFR-targeted
therapies have been developed, including monoclonal antibodies against the extracellular
domain of EGFR and tyrosine kinase inhibitors (TKIs) [70,79].
Cetuximab is a recombinant human/mouse chimeric EGFR antagonist mAb of IgG1
isotype that binds to the extracellular ligand-binding domain of the EGFR, blocks the
binding of EGF and other ligands to the EGFR and the ligand-induced phosphorylation
and activation of EGFR and downstream cell signalling molecules, ultimately leading
to tumour growth inhibition and apoptosis [80]. It is FDA approved for the treatment
of metastatic colorectal cancer and head and neck squamous cell carcinoma (Table 1).
Phase 2 trials in patients with pancreatic cancer showed that the addition of cetuximab to
docetaxel/irinotecan or gemcitabine did not offer any survival benefit [81,82]. Similarly,
a phase 3 study in patients with advanced pancreatic cancer showed that the addition of
cetuximab to gemcitabine did not improve outcomes [83]. In contrast, a phase 2 study
reported that cetuximab and bevacizumab in combination with gemcitabine, cisplatin and
fluorouracil lengthens overall survival by ~6 months and PFS by ~3 months in patients with
advanced pancreatic cancer [84]. However, a recent systematic review and meta-analysis
concludes that adding cetuximab to standard therapy for the treatment of pancreatic cancer
is not beneficial [85]. Tumour heterogeneity and lack of reliable predictive biomarkers for
the response to therapy may be some of the contributing factors for these discouraging
results to date.
Panitumumab is a fully human antibody of IgG2 isotype (i.e. has no ADCC function)
to the EGFR. Like cetuximab, it also inhibits the binding of ligands to the EGFR and subse-
quent downstream cell signalling pathways but it has no ADCC and CDC functions [86].
It is FDA approved for the treatment of patients with metastatic colorectal cancer (Table 1).
A phase 1 study showed that the addition of panitumumab to gemcitabine-based chemora-
diotherapy has manageable toxicity and suggests some efficacy in patients with locally
advanced pancreatic cancer [87]. In addition, a phase 2 trial evaluating the combination of
panitumumab, erlotinib and gemcitabine compared with erlotinib and gemcitabine alone
in patients with metastatic pancreatic cancer demonstrated significant improvement in
overall survival (8.3 vs. 4.2 months) although this regimen was associated with increased
toxicity [88]. On the other hand, panitumumab-IRDye800, a fluorescently labelled antibody,
which previously was found to be highly sensitive and specific for detection of tumours
within 5mm in head and neck cancers [89], demonstrated in a phase 1 trial that is safe and
might allow direct visualisation during pancreatic cancer surgery [90].
Nimotuzumab is an IgG1 humanised mAb directed against the extracellular domain
of EGFR that has also been reported to induce an adaptive immune response [91]. Phase 2
studies have shown that nimotuzumab is safe and well tolerated alone and in combination
with gemcitabine, and the combination regimen showed significant improvement in 1-year
OS and PFS rates [92,93]. On the other hand, matuzumab (formerly EMD 72000) is a
humanised IgG1 mAb to EGFR that demonstrated being safe and well tolerated in a
phase 1 trial in combination with gemcitabine [94]. The results of future clinical trials using
more reliable biomarkers for the response to therapy with anti-EGFR mAbs may lead to the
approval of anti-EGFR mAbs in a more specific population of pancreatic cancer patients.
4.3. Clinical Trials with the Anti-Human Epidermal Growth Factor Receptor 2 (HER2)
Antibody Trastuzumab
HER2, another member of the HER family of growth factor receptor tyrosine kinases, is
considered to play a vital role in carcinogenesis. HER2 amplification and/or overexpression
has been associated with the development of pancreatic cancer, with reported rates of
overexpression ranging between 4 and 50% [70,95].
Trastuzumab is a humanised IgG1 antibody that targets the extracellular domain
of HER2, triggers receptor internalisation and degradation, exhibits ADCC activity and
inhibits the MAPK and PI3K/Akt pathways leading to increased cell cycle arrest and cell
growth suppression [96]. It is FDA approved for treatment of breast cancer and metastatic
gastric or gastroesophageal junction adenocarcinoma (Table 1). The results of Phase 1/2
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clinical trials of trastuzumab in combination with cetuximab or capecitabine did not
demonstrate improvement in objective response and/or survival rates in pancreatic can-
cer patients [97,98].
4.4. Clinical Trials with the Anti-Vascular Endothelial Growth Factor (VEGF) Antibody Bevacizumab
Vascular endothelial growth factor (VEGF) is a major driver of tumour angiogenesis
and as such, has attracted interest for use in cancer therapy. VEGFA is secreted by tumour
cells and surrounding stroma and binds to VEGFR2 (VEGF receptor-2) activating the
Ras-Raf-MAPK-ERK signalling pathway stimulating the proliferation and survival of
endothelial cells, leading to angiogenesis and formation of leaky and structurally abnormal
blood vessels [99].
Bevacizumab is a humanised IgG1 monoclonal antibody that targets VEGF, neutraliz-
ing the ligand and preventing the interaction with its receptor on the surface of endothelial
cells, ultimately inhibiting endothelial proliferation and angiogenesis [86]. It is FDA ap-
proved for the treatment of patients with metastatic colorectal cancer, non-small cell lung
cancer, glioblastoma, metastatic renal cell carcinoma, metastatic HER2-negative breast
cancer, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer
(Table 1). Unfortunately, the results of phase 3 trials have shown that the addition of
bevacizumab to gemcitabine or to gemcitabine-erlotinib did not improve overall survival
in patients with advanced pancreatic cancer [100,101].
4.5. Clinical Trials with Anti-Cytotoxic Lymphocyte-Associated Antigen-4 (CTLA-4)
Cytotoxic lymphocyte-associated antigen-4 (CTLA-4) is an immune checkpoint pro-
tein constitutively expressed on regulatory T cells that modulates T cell activation and
suppressive properties of APCs (antigen presenting cells). CTLA-4 binds competitively to
B7 ligands (CD80 and CD86) expressed on APCs with higher affinity than the co-receptor
CD28, which activates naive T cells (Figure 1). CTLA-4 blockade would result in regulatory
T cell depletion, T cell enhancement and tumour reduction [102,103].
Ipilimumab is an IgG1 monoclonal antibody against the extracellular domain of
CTLA-4 that prevents T cell suppression by inhibitory immune checkpoints, resulting in
a potent anti-tumour effect by enhancing effector cells and inhibiting regulatory activity
of T cells [86,102]. It has been approved by the FDA for the treatment of patients with
melanoma, advanced renal cell carcinoma and microsatellite instability-high (MSI-H) or
mismatch repair deficient (dMMR) metastatic colorectal cancer (Table 1). Despite the fact
that a phase 2 trial of ipilimumab alone in locally advanced and metastatic pancreatic
cancer showed to be ineffective [104], a subsequent study of ipilimumab combined with
GM-CSF cell-based vaccines (GVAX) showed improved median overall survival and 1-year
OS compared to ipilimumab alone, warranting further studies [105].
On the other hand, tremelimumab (CP-675,206) is a fully human IgG2 mAb directed
against CTLA-4 without FDA approvals at present. A phase 1 trial of tremelimumab plus
gemcitabine in patients with metastatic pancreatic cancer demonstrated to be safe and
tolerable [106], while a phase 2 study with tremelimumab monotherapy did not show
activity in metastatic pancreatic cancer patients who had tumour progression following
first-line chemotherapy [107].
4.6. Clinical Trials with Anti-Programmed Cell Death-1 (PD-1) Receptor and Anti-PD-L1
Ligand Antibodies
The programmed cell death-1 receptor (PD-1) is expressed on the surface of immune
effector cells and upon binding to its ligands, PD-L1 and PD-L2, suppresses proliferation
and immune response of T-cells. Activation of this pathway allows evasion of immune
response by cancer cells, and blockade of the axis enhances anti-tumour activity [108].
Pembrolizumab is a humanised anti-PD1 IgG4 mAb approved for the treatment of
melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, clas-
sical Hodgkin lymphoma, urothelial carcinoma, gastric or gastroesophageal junction
adenocarcinoma, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, re-
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nal cell carcinoma, squamous cell lung cancer, endometrial carcinoma, BCG-unresponsive
high-risk non-muscle invasive bladder cancer, tumour mutational burden-high (TMB H)
solid tumours, cutaneous squamous cell carcinoma, MSI-H or dMMR colorectal cancer
and locally recurrent unresectable or metastatic triple negative breast cancer whose tu-
mours express PD-L1, with a number of indications that is rapidly expanding (Table 1).
A phase 1b study of pembrolizumab in combination with the oncolytic virus pelareorep
and chemotherapy showed encouraging efficacy [109] and a phase 2 trial is currently
ongoing (NCT03723915, Table 6). On the other hand, a phase 1b/2 study of gemcitabine,
nab-paclitaxel, and pembrolizumab showed median PFS and OS of 9.1 and 15.0 months
respectively, in chemotherapy-naive pancreatic cancer patients, which indicates a slight im-
provement compared to previous results for gemcitabine and nab-paclitaxel regimens [110].
Pembrolizumab is also currently being evaluated in phase 1 and 2 trials in combina-
tion with either olaparib (NCT04548752), paricalcitol +/– gemcitabine and nab-paclitaxel
chemotherapy (NCT02930902) or PEGPH20, a PEGylated version of human recombinant
PH20 hyaluronidase (NCT03634332, Table 6).
The COMBAT phase 2 trial evaluated the safety and efficacy of pembrolizumab in
combination with the CXCR4 antagonist BL-8040 (motixafortide) in patients with metastatic
pancreatic cancer and demonstrated disease control rate (DCR) of 34.5%. In the group
receiving study drugs as second-line therapy, the median OS was 7.5 months and 6-month
survival rate was 56.3%, suggesting that this combination warrants further investigation.
Preliminary results show that along with chemotherapy this combination may provide
additional benefit (ORR 32%, DCR 77%) [111]. A phase 2 study will be further evaluating
the efficacy of pembrolizumab in combination with BL-8040 (NCT02907099).
Nivolumab is a humanised IgG4 anti-PD1 mAb approved for the treatment of melanoma,
non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, head and
neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular car-
cinoma, small cell lung cancer, oesophageal squamous cell carcinoma and unresectable
malignant pleural mesothelioma (Table 1). A phase 1 study of nivolumab in combination
with nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer showed
that the combination was safe although the efficacy does not support further investiga-
tion [112]. Several studies investigating nivolumab in combination with other agents are
underway. For instance, a phase 1/2 trial evaluating nivolumab plus mFOLFIRINOX in
patients with borderline resectable disease (NCT03970252), a phase 1/2 study investigating
the combination of nivolumab plus BMS-813160 (a CCR2/CCR5 dual antagonist) with or
without GVAX (an allogeneic GM-CSF–transfected pancreatic tumour vaccine) in locally
advanced pancreatic cancer (NCT03767582), and phase 1 trials evaluating the safety and
tolerability of the combination of nivolumab with either intratumoural SD-101 (a TLR9
agonist) and radiation therapy (NCT04050085), or SX-682 (a small-molecule dual-inhibitor
of chemokine receptors CXCR1 and CXCR2) in patients with metastatic pancreatic cancer
(NCT04477343, Table 6).
Clinical trials are also ongoing evaluating anetumab ravtansine (an anti-mesothelin
ADC) and nivolumab either alone or in combination with ipilimumab or gemcitabine
(NCT03816358), and a phase 1/2 study evaluating the combination of APX005M (a CD40
agonistic mAb), gemcitabine and nab-paclitaxel with or without nivolumab (NCT03214250,
Table 6).
On the other hand, durvalumab (MEDI4736) is a human IgG1κ mAb that selectively
blocks PD-L1 binding to PD-1 and CD-80, potentiating an immune response to tumour
cells [113]. A phase 2 trial evaluating durvalumab with or without tremelimumab in
patients with metastatic pancreatic cancer was well tolerated but did not progress further as
the threshold for efficacy was not met in the first part of the study [114]. In addition, a phase
1/2 trial evaluating the combination of guadecitabine and durvalumab in patients with
advanced hepatocellular carcinoma, pancreatic cancer or cholangiocarcinoma is currently
ongoing (NCT03257761, Table 6).
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Other anti-PD1 antibodies are also being evaluated in clinical trials in patients with
metastatic pancreatic cancer including a phase 1/2 study of spartalizumab in combination
with the anti-IL6 mAb siltuximab (NCT04191421), a phase 2 trial of camrelizumab in com-
bination with nab-paclitaxel and gemcitabine (NCT04498689), a phase 1 study of the mAb
SHR-1210 in combination with paclitaxel-albumin and gemcitabine (NCT04181645), a phase
2 trial of dostarlimab (TSR-042) in combination with niraparib (NCT04493060), a phase 1
trial of spartalizumab in combination with nab-paclitaxel, gemcitabine and the anti-IL-1β
mAb canakinumab (NCT04581343), a phase 1 study of zimberelimab (AB122) in combina-
tion with AB680 (a CD73 inhibitor), nab-paclitaxel and gemcitabine (NCT04104672), and
a phase 3 trial of anti-PD-1 antibody plus modified FOLFIRINOX (NCT03983057). See
Table 6.
Finally, a phase 2 trial is evaluating INCMGA00012 (a humanised mAb antagonistic
to PD-1) in patients with unresectable or metastatic adenosquamous pancreatic cancer, a
rare and more aggressive pancreatic cancer subtype, with worse survival outcomes than
pancreatic adenocarcinoma (NCT04116073) [115].
4.7. Clinical Trial with Anti-Hepatocyte Growth Factor (HGF) Antibody Ficlatuzumab
Hepatocyte growth factor (HGF) is a glycoprotein produced by mesenchymal cells of
stromal origin that, upon binding to its receptor, leads to dimerisation and phosphorylation
of c-MET with subsequent activation of signalling pathways such as MAPK and PI3K,
regulating cell proliferation, migration and invasion [116]. Expression of HGF and c-MET
are upregulated in pancreatic cancer and are associated with poor prognosis [117,118].
Ficlatuzumab (AV-299) is a humanised hepatocyte growth factor (HGF) IgG1κ mAb
that interferes with the binding of HGF to c-Met receptor tyrosine kinase, inhibiting
phosphorylation, cell proliferation, migration and invasion [119]. Ficlatuzumab is currently
being evaluated in a phase 1b trial in combination with gemcitabine and nab-paclitaxel in
patients with advanced pancreatic cancer (NCT03316599, Table 6).
4.8. Clinical Trial with Anti-Lysyl Oxidase-Like 2 (LOXL2) Antibody Simtuzumab
Lysyl oxidase-like 2 (LOXL2) is an extracellular matrix-remodelling enzyme that catal-
yses the cross-linking of collagen and elastin components and is expressed in desmoplastic
tumours. LOXL2 promotes epithelial-to-mesenchymal transition and downregulates E-
cadherin expression in various cancer types [120–122]. It is thought to promote tumour
angiogenesis and metastases, has been associated with pancreatic cancer progression and
has been reported as a prognostic biomarker in patients who have undergone surgical
resection [120,121]. Simtuzumab is a humanised IgG4 mAb that targets LOXL2, inhibiting
its enzymatic activity. A phase 2 randomised trial evaluating simtuzumab in combina-
tion with gemcitabine failed to show improvement in PFS, OS or ORR in patients with
metastatic pancreatic cancer [121].
4.9. Clinical Trials with Anti-Death Receptor 5 (DR5) Antibodies
Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a trans-
membrane protein that, upon binding to death receptors DR4 and DR5, activates the
caspase cascade leading to apoptotic cell death via the extrinsic pathway [123]. Thus,
agonistic antibodies against DR4 and DR5 have shown to induce apoptosis in tumour cells
and enhance tumour sensitivity to chemotherapy, radiotherapy and targeted therapy [123].
Conatumumab (AMG655) is a fully human IgG1 antibody to human death receptor 5
(DR5) that induces apoptosis by caspase activation [124]. A phase 2 study of the combina-
tion of gemcitabine plus conatumumab in patients with previously untreated metastatic
pancreatic adenocarcinoma showed trend towards improved 6-month survival rate (59%
compared to 50% in the gemcitabine plus placebo arm) although 12-month survival rate,
OS and ORR were not significantly different [73].
Tigatuzumab (CS-1008) is a humanised IgG1 version of TRA-8, a murine agonist
mAb to DR5 [125]. A phase 2 study of tigatuzumab in combination with gemcitabine in
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patients with unresectable or metastatic pancreatic cancer, showed PFS rate at 16 weeks
of 52.5% and median OS of 8.2 months. These results are similar to previous studies with
gemcitabine in combination with other agents, suggesting that this combination may be
clinically active although no definitive conclusions were drawn on the benefit of adding
tigatuzumab [126].
4.10. Clinical Trials with Anti-CA19-9 Antigen (CA19-9) Antibodies
Carbohydrate antigen 19-9 (CA19-9), also known as sialyl Lewis A (sLea), is the
most widely used and best validated diagnostic and prognostic biomarker in pancreatic
cancer, being a useful predictor of tumour stage and resectability, response to therapy
and overall survival. However, the predictive positive value is low and is therefore
not used in the screening of asymptomatic patients. It has been implicated with the
pathogenesis of pancreatic cancer, making it an attractive therapeutic target [127,128].
Preliminary phase 1 data of MVT-5873 (HuMab-5B1), a fully human IgG1 mAb targeting
sLea, showed encouraging response as single agent or in combination with nab-paclitaxel
and gemcitabine in CA19-9 positive pancreatic cancer patients [114]. In addition, the
radiolabelled mAb HuMab-5B1 (MVT-2163), which recognises the cancer antigen CA19-
9, demonstrated visualisation of primary tumours and metastases by immune-PET in a
phase 1 study [129]. Phase 1 and 2 clinical trials evaluating MVT-5873 in patients with
CA19-9 overexpressing tumours are currently ongoing (NCT03801915, NCT03118349 and
NCT02672917, Table 6).
4.11. Clinical Trial with Anti-Guanylyl Cyclase C (GCC) Antibody
Guanylyl cyclase C (GCC) is a transmembrane G protein cell surface receptor that plays
a role in the regulation of fluid and electrolyte balance. It is highly expressed in colorectal
cancer and in around 60–70% of pancreatic cancers [130,131]. TAK-264 (MLN0264) is an
antibody-drug conjugate consisting of a fully human IgG1 mAb against GCC, conjugated
to MMAE (monomethyl auristatin E) that, once internalised, leads to cell cycle arrest
and apoptosis [130]. A phase 2 study of the ADC TAK-264 in patients with advanced or
metastatic pancreatic cancer expressing GCC showed a manageable safety profile but low
efficacy, which does not support further studies [132].
4.12. Clinical Trial with Anti-SLC44A4 Antibody ASG-5ME
SLC44A4 (CTL4) is a protein differentially expressed in prostate and pancreatic cancers
with low expression in normal tissues [60]. ASG-5ME is an ADC formed by a human
IgG2 antibody against SLC44A4 conjugated with monomethyl auristatin E (MMAE) [60].
A phase 1 study of ASG-5ME in patients with advanced pancreatic and gastric cancers
showed that it was well tolerated but had limited efficacy [133].
4.13. Clinical Trial with Anti-CD40 Antibody Selicrelumab
CD40 (cluster of differentiation 40) is a cell surface molecule, member of the tumour
necrosis factor family, that is expressed on antigen-presenting cells such as dendritic cells
and myeloid cells, and in a variety of cancer types with very low or no expression in normal
cells [134]. CP-870,893 (selicrelumab) is a fully human IgG2 CD40-agonist mAb. A phase 1
study of CP-870,893 plus gemcitabine in patients with advanced pancreatic cancer showed
that it was well tolerated and was associated with preliminary evidence of efficacy [135].
4.14. Clinical Trial with Anti-Prostate Stem Cell Antigen (PSCA) Antibody AGS-1C4D4
Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored
cell surface protein associated with various cancer types such as prostate, bladder, gas-
tric and pancreatic cancer, that has been proposed as a biomarker for detection of circu-
lating tumour cells (CTCs) and for cytological examination of specimens in pancreatic
cancer patients [136,137]. AGS-1C4D4, a fully human IgG1κ mAb against PSCA, was
evaluated in a phase 2 trial in combination with gemcitabine and demonstrated an im-
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provement in 6-month survival rate in the combination arm versus gemcitabine alone
(60.9% vs 44.4%) [138].
The list of currently ongoing clinical trials with antibody-based agents in combination
with other therapeutics in patients with pancreatic cancer are summarised in Table 6. The
results of such trials should help to unravel whether treatment with such agents lead to
long-term therapeutic benefits in pancreatic cancer patients and the underlying mechanism
of response or resistance to such therapeutic interventions.
Table 4. Phase I/II clinical trials of monoclonal antibodies alone or in combination with other drugs in pancreatic cancer
(www.clinicaltrials.gov accessed on 17 March 2021).
Condition/Stage of
Disease
Therapeutic Intervention n Ph Outcomes Ref.
Metastatic PC
Durvalumab + tremelimumab vs.
durvalumab
65 II
ORR: 3.1 vs. 0%
Not enrolled in part B because the




Olaratumab + nab-paclitaxel +
gemcitabine
10 I




Gemcitabine + MK-0646 (arm A)
vs. gemcitabine + MK-0646 +
erlotinib (arm B) vs. gemcitabine
+ erlotinib (arm C)
81 I/II
PFS: 1.8 vs. 1.8 vs. 1.9 months




MVT-5873 + nab-paclitaxel +
gemcitabine
38 I
Single agent MVT-5873 appears safe












Cetuximab or bevacizumab +
gemcitabine + chemoradiation
127 II





Gemcitabine + nimotuzumab vs.
gemcitabine + placebo
192 IIb
mOS: 8.6 vs. 6.0 months (p = 0.03)




TAK-264 (MLN0264) 43 II ORR: 3% [132]
Metastatic PC
Gemcitabine + simtuzumab
(700 mg) vs. gemcitabine +
simtuzumab (200 mg) vs.
gemcitabine + placebo
240 II
mPFS: 3.7 (p = 0.73) vs. 3.5 (p = 0.61)
vs. 3.7 months
mOS: 7.6 (p = 0.28) vs. 5.9 (p = 0.69)
vs. 5.7 months








I Safe and well tolerated [142]
Unresectable PC
Bevacizumab + erlotinib +
capecitabine + RT
17 I Safe and well tolerated [143]
PC not amenable to
curative treatment
Bevacizumab + cetuximab +
leucovorin + gemcitabine +
cisplatin + fluorouracil vs.
leucovorin + gemcitabine +
cisplatin + fluorouracil
59 II
mOS: 13.2 vs. 6.8 months (p = 0.03)





Well tolerated with limited evidence
of antitumour activity
[133]




Therapeutic Intervention n Ph Outcomes Ref.
Locally advanced PC
Neoadjuvant gemcitabine plus
capecitabine, followed by either:
capecitabine or UFT + RT (A) or
capecitabine or UFT + cetuximab
+ RT (B).
17 II
mOS: 15.8 vs. 22.0 months (p > 0.05)
mPFS: 10.4 vs. 12.7 months (p > 0.05)
[144]
Metastatic PC
Irinotecan + docetaxel vs
irinotecan + docetaxel +
cetuximab
87 II
ORR: 4.5 vs. 7%
mPFS: 3.9 vs. 4.5 monthsmOS: 6.5 vs.
5.3 months
[82]







mOS: 2.7 vs. 2.6 months (7.9 vs.
3.4 months in patients who received











Trastuzumab + cetuximab (after






Gemcitabine + erlotinib +
cixutumumab vs. gemcitabine +
erlotinib
116 Ib/II
mPFS: 3.6 vs. 3.6 months (p = 0.97)
mOS: 7.0 vs. 6.7 months (p = 0.64)
[76]









































Advanced PC CP-870,893 + gemcitabine 22 I







Ipilimumab vs. ipilimumab +
GVAX




followed by RT + bevacizumab
59 II
mOS: 16.8 months (19.7 months
after resection)
mPFS: 6.6 months (12.9 months
after resection)
[151]
R0 or R1-resected PC Gemcitabine + cetuximab 76 II








Therapeutic Intervention n Ph Outcomes Ref.
Metastatic PC
Gemcitabine vs. gemcitabine +
AGS-1C4D4
196 II
6-month SR: 44.4 vs. 60.9% (P = 0.03)
mOS: 5.5 vs. 7.6 months (p = 0.12)
mPFS: 3.2 vs. 3.8 months (p = 0.27)
ORR: 13.1 vs. 21.6%
[138]
Advanced PC







Bevacizumab + gemcitabine +
5-FU
42 II





Gemcitabine + ganitumab vs.
gemcitabine + conatumumab vs.
gemcitabine + placebo
125 II
6-month SR: 57 vs. 59 vs. 50%
mOS: 8.7 vs. 7.5 vs. 5.9 months
mPFS: 5.1 vs.. 4.0 vs. 2.1 months







mOS: 24.3 (resected patients) vs.
10 months (not resected)
[154]










Trastuzumab + capecitabine 17 II




Bevacizumab + cetuximab +
gemcitabine vs. bevacizumab +
cetuximab
61 II
mPFS: 3.5 vs. 1.9 months



















Cetuximab + gemcitabine +
oxaliplatin
64 II
mOS: 263 vs.. 162 days (WT vs.
KRAS mutation)




Cetuximab + gemcitabine +
oxaliplatin followed by cetuximab





Advanced PC 90Y-clivatuzumab tetraxetan 21 I

















Locally advanced PC Gemcitabine + cetuximab + RT 16 I









mPFS: 43 vs. 48 days
mOS: 165 vs. 125 days
The study was stopped due to futility.
[164]








No responders but one subject






Bevacizumab + erlotinib 36 II OS at 6 months: 22% [165]
Locally advanced or
metastatic PC









Bevacizumab + capecitabine + RT 82 II
mOS: 11.9 months
1-year survival: 47%





































Cetuximab + gemcitabine +
cisplatin vs. gemcitabine +
cisplatin alone
84 II
ORR: 17.5 vs. 12.2% (p = 0.55)
mPFS: 3.4 vs. 4.2 months (p = 0.85)
mOS: 7.5 vs. 7.8 months (p = 0.74)
[172]
Untreated stage III or
IV PC


























Murine mAb 17-1A 28 II
Acceptable toxicity. Lack of efficacy
of treatment
[176]
CEA: carcinoembryonic antigen; DCR: disease control rate; DFS: disease free survival; GVAX: GM-CSF cell-based vaccines; IMRT: intensity-
modulated radiotherapy; mOS: median overall survival; mPFS: median progression-free survival; mTTP: median time to progression;
mTTF: median time to treatment failure; n: number of patients; ORR: Objective response rate; PKs: pharmacokinetics; PR: partial response;
RAIT: radioimmunotherapy; SD: stable disease; SR: survival rate; TTP: time to progression; WT: wild-type.
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Table 5. Phase III clinical trials of monoclonal antibodies alone or in combination with other drugs for pancreatic cancer
treatment (www.clinicaltrials.gov accessed on 17 March 2021).
Condition/Stage of
Disease
Therapeutic Intervention n Ph Outcomes Ref.
Metastatic PC
(GAMMA trial)
Gemcitabine + placebo vs..
gemcitabine + ganitumab (12 mg/kg)
vs. gemcitabine + ganitumab
(20 mg/kg)
800 III
mOS: 7.2 vs. 7.0 (p = 0.49) vs.




Gemcitabine + bevacizumab vs.
gemcitabine + placebo
602 III
mOS: 5.8 vs. 5.9 months (p = 0.95)





PC (SWOG S0205 trial)
Gemcitabine vs. gemcitabine +
cetuximab
745 III
mOS: 5.9 vs. 6.3 months (p = 0.19)
mPFS: 3.0 vs. 3.4 months (p < 0.18)
mTTF: 1.8 vs. 2.3 months (p < 0.006)
ORR: 14 vs. 12% (p = 0.59)
[83]
Metastatic PC
Gemcitabine + erlotinib +
bevacizumab vs. gemcitabine +
erlotinib + placebo
607 III
mOS: 7.1 vs. 6.0 months (p < 0.21)
mPFS: 4.6 vs. 3.6 months (p < 0.0002)
ORR: 13.5 vs. 8.6% (p < 0.06)
[100]
n: number of patients.
Table 6. Selected ongoing clinical trials evaluating monoclonal antibodies alone or in combination with other drugs in
pancreatic cancer (www.clinicaltrials.gov accessed on 17 March 2021).





Pembrolizumab (anti-PD-1 mAb) + paricalcitol vs..




NCT03723915 Pembrolizumab (anti-PD-1 mAb) + pelareorep 30 II
Active, not recruiting
(06/2021)
NCT04548752 Olaparib + pembrolizumab (anti-PD-1 mAb) vs. olaparib 88 II
Not yet recruiting
(03/2025)
NCT02907099 BL-8040 + pembrolizumab (anti-PD-1 mAb) 23 II
Active, not recruiting
(12/2022)
NCT03634332 PEGPH20 + pembrolizumab (anti-PD-1 mAb) 35 II Recruiting (01/2021)
NCT04477343
SX-682 (dual-inhibitor CXCR1/CXCR2) + nivolumab
(anti-PD-1 mAb)
20 I Recruiting (10/2022)
NCT03970252 Nivolumab (anti-PD-1 mAb) + mFOLFIRINOX 36 I, II Recruiting (04/2022)
NCT04050085
SD-101 (TLR9 agonist) + radiation therapy + nivolumab
(anti-PD-1 mAb)
6 I Recruiting (11/2021)
NCT03767582
Nivolumab + CCR2/CCR5 dual antagonist vs.
Nivolumab + GVAX + CCR2/CCR5 dual antagonist
30 I, II Recruiting (03/2022)
NCT03214250
APX005M (CD40 agonistic mAb) + nivolumab (anti-PD-1 mAb) +






Surgery vs. VX15/2503 + surgery vs. VX15/2503 + ipilimumab
(anti-CTLA-4 mAb) + surgery vs. VX15/2503 + nivolumab
(anti-PD-1 mAb) + surgery
32 I Recruiting (12/2022)
NCT04191421 Siltuximab (anti-IL-6) + spartalizumab (anti-PD-1 mAb) 42 I, II Recruiting (12/2022)
NCT04581343
Canakinumab (anti-IL-1β mAb) + spartalizumab (anti-PD-1 mAb)
+ nab-paclitaxel + gemcitabine
10 I Recruiting (03/2022)
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Table 6. Cont.
Trials Identifier Therapeutic Intervention n 1 Ph
Study Status
(Completion Date)
NCT04116073 INCMGA00012 (anti-PD-1 mAb) 25 II Recruiting (08/2028)
NCT03983057 mFOLFIRINOX + anti-PD-1 antibody vs. mFOLFIRINOX 830 III Recruiting (04/2022)
NCT04498689 Camrelizumab (anti-PD-1 mAb) + nab-paclitaxel + gemcitabine 117 II Recruiting (12/2022)
NCT03989310
Manganese primed anti-PD-1 antibody +
nab-paclitaxel + gemcitabine
20 I, II Recruiting (03/2021)
NCT04104672
AB680 (CD73 inhibitor) + zimberelimab (anti-PD-1 mAb) +
nab-paclitaxel + gemcitabine
150 I Recruiting (01/2024)
NCT04181645 SHR-1210 (anti-PD-1 mAb) + paclitaxel-albumin + gemcitabine 20 I Recruiting (07/2022)




Anetumab ravtansine (anti-mesothelin ADC) + nivolumab
(anti-PD-1 mAb) vs. anetumab ravtansine + nivolumab +
ipilimumab vs. anetumab ravtansine + nivolumab + gemcitabine
64 I, II Recruiting (04/2021)
Anti-CLDN18.2 mAb
NCT03816163
Zolbetuximab (anti-CLDN18.2 mAb) + nab-paclitaxel +
gemcitabine vs. nab-paclitaxel + gemcitabine
141 II Recruiting (10/2022)
Anti-PDGFRα mAb
NCT03086369
Olaratumab (anti-PDGFRα mAb) + nab-paclitaxel + gemcitabine





NCT03801915 MVT-5873 (anti-Sialyl Lewis/CA19.9 mAb) 105 II Recruiting (12/2023)
NCT03118349 MVT-5873 (anti-Sialyl Lewis/CA19.9 mAb) + MVT-1075 7 I
Active, not recruiting
(12/2020)
NCT02672917 MVT-5873 (HuMab-5B1) 108 I Recruiting (12/2020)
Anti-OX40 mAb




NCT03316599 Ficlatuzumab (anti-HGF mAb) + gemcitabine + nab-paclitaxel 26 Ib
Active, not recruiting
(11/2023)
1 Estimated enrolment. mFOLFIRINOX: modified FOLFIRINOX. Taken from: https://www.clinicaltrials.gov/ct2/home (accessed on 17
March 2021). Updated as of 10 January 2021.
5. Challenges and Future Opportunities with Antibody Therapeutics in Pancreatic Cancer
As the results of preclinical and clinical studies discussed above and presented in
summary tables suggest, the application of monoclonal antibody-based agents in the
treatment of pancreatic cancer is more likely to be successful when used in combination
with other therapies such as cytotoxic drugs, other mAbs, cancer vaccines and/or oncolytic
viruses. In addition, simultaneous targeting of signalling pathways, the tumour stroma and
the incorporation of immune checkpoint inhibitors could yield better results by modifying
the immunosuppressive environment of pancreatic tumours [70,177–181].
Remarkable responses to immunotherapy have been shown in patients with several
types of solid tumours including melanoma [182,183], non-small cell lung cancer [184–186]
and renal cell carcinoma [184–186]. However, immunotherapy with checkpoint inhibitors
in unselected pancreatic cancer patients has not demonstrated clinical efficacy, partly due
to the strong immunosuppressive tumour microenvironment and the poor antigenicity
of tumour-associated antigens that elicit immune response [103,187]. Pancreatic cancer
microenvironment is characterised by dense desmoplasia, hypovascularity and scanty im-
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mune effector cells [178,188,189]. Therefore, targeting the tumour stroma is of paramount
importance to increase drug delivery, promote T-cell infiltration and activation, and over-
come the barriers posed by tumour immune-escape mechanisms and the immunosuppres-
sive environment [190]. The CXCRL12/CXCR4 axis has been implicated in all stages of
pancreatic cancer development and contributes to survival, metastasis, chemoresistance
and the highly atypical pancreatic cancer microenvironment, which makes this disease
particularly difficult to treat [191]. Thus, systemic therapies along with simultaneous
targeting of the CXCRL12/CXCR4 axis might be an attractive therapeutic approach.
On the other hand, chimeric antigen receptor (CAR) T cell therapy has emerged in
recent years as an attractive alternative for cancer treatment (please see Leonardi et al.,
in this special issue [192]). CD19 targeted CAR T cells have been approved for the treat-
ment of acute lymphoblastic leukaemia [193], relapsed/refractory diffuse large B-cell
lymphoma [194–196] and relapsed/refractory follicular lymphoma [197]. More recently,
the B-cell maturation antigen (BCMA)-directed genetically modified autologous CAR T-cell
therapy idecabtagene vicleucel has been approved for relapsed or refractory multiple
myeloma [198]. Other studies have evaluated the feasibility of various chimeric antigen
receptor (CAR)-modified T cells recognising antigens such as mesothelin [199] and glypican-
1 [200] in solid tumours including pancreatic cancer. Currently, several clinical trials are
underway with CAR T cells targeting mesothelin (NCT03638193, NCT03323944), CEA
(NCT03818165, NCT04037241, NCT02850536) and claudin 18.2 (NCT04404595, NCT04581473)
and the results should unravel whether such treatments can be of therapeutic value in
patients with pancreatic cancer. In particular, results of clinical trials evaluating the combi-
nation of immune checkpoint inhibitors, cancer vaccines and agents that target the immuno-
suppressive microenvironment in pancreatic cancer are eagerly anticipated. Preclinical
studies in subcutaneous and metastatic pancreatic cancer mouse models demonstrated that
the combination of a T-cell vaccine, a PD-1 antagonist and a CD40 agonist mAb was able
to eradicate most tumours, favouring antitumour immunity by reprogramming immune
resistant tumours [201]. This might become a promising approach in the clinical setting.
A better understanding of the biology of pancreatic cancer and the interplay between
pancreatic cancer cells, stellate cells and the microenvironment would provide a more
solid rationale for the development of new therapeutics including mAb-based agents.
Indeed, to improve survival rates, it is clear that there is an urgent need for the discovery
of additional cell surface antigens with high levels of expression in patients at different
stages of pancreatic cancer. There are currently several approaches for the discovery of
membranous proteins such as monoclonal antibody technology or membrane proteomics
analysis of isolated proteins by SDS-PAGE and mass spectrometry [66,202]. Indeed, using
monoclonal antibody technology and human pancreatic cancer cell lines established from
primary tumours and metastatic sites, both as the source of tumour immunogen and in the
antibody screening, we have reported recently the development of three novel antibodies.
We found that the antigens recognised by these three novel mAbs were CD109, integrin
α3 and CD26, with high levels of expression in several human pancreatic cancer cells and
Pancreatic Cancer Tissue microarray [26,66]. Indeed, antibody-based screening will help
not only in the discovery of additional therapeutic cell surface antigens with high levels of
expression at different stages of pancreatic cancer (i.e., therapeutic targets) but also in the
development of antibody-based agents for therapy. Moreover, such antibodies would be
excellent tools for investigating the diagnostic, prognostic and predictive values of such
antigens and investigating their roles in the complex biology of pancreatic cancer [58].
6. Summary and Concluding Remarks
Pancreatic cancer is one of the deadliest cancer types, with mortality rates that almost
equal its incidence. Despite some advances in diagnosis and treatment, its five-year survival
rate has not improved substantially over the past few decades. Due to its rising incidence,
pancreatic cancer is predicted to become the second leading cause of cancer death by 2030 in
many countries [1,4]. Therefore, in order to improve prognosis for patients with pancreatic
Cancers 2021, 13, 1781 26 of 38
cancer, it is vital to avoid modifiable risk factors, to discover novel biomarkers/screening
methods for its earlier detection, to identify additional targets, and to develop more specific
therapeutic agents and companion diagnostic tests for the selection of a more specific
population of patients who are more likely to benefit from therapeutic interventions with
mAb-based agents.
The development of monoclonal antibodies against overexpressed cell surface antigens
in pancreatic cancer is an attractive strategy for use in both diagnosis and treatment [58].
Since the invention of the hybridoma technology, efforts have been made to develop mAbs
for the treatment of different cancer types. Despite success in the application of this form
of therapy and subsequent approval by regulatory bodies in haematological malignancies
and various solid tumours, none of these mAbs have been approved for pancreatic cancer
as of yet (Table 1).
Monoclonal antibodies therapy offers some advantages over other forms of therapy
such as target specificity, reduced toxicity and the potential to trigger immune system
activation. However, the modest efficacy, the lack of biomarkers predictive of response and
the high cost of antibody production are currently some of the major drawbacks of the use
of this form of therapy [14,15].
In pancreatic cancer, as well as in other solid tumours, monoclonal antibodies used as
single agents have limited efficacy. Therefore, different treatment combinations have been
used in an attempt to improve activity and deliver better survival outcomes (Tables 4 and 5).
Various approaches have been postulated including the combination of two or more mAbs
directed against different targets, the combination of mAbs with standard of care chemother-
apy, the combination of mAbs with radiotherapy to sensitise tumours, the simultaneous
targeting of the vasculature and stroma, the targeting of coinhibitory receptors on effector
T cells, and the use of bispecific antibodies to bring effector T cells and NK cells in proximity
to tumour cells.
To date, monoclonal antibodies targeting IGF-IR, HER2 and VEGF, or combinations of
these, have not shown encouraging results in pancreatic cancer patients [74,76,97,98,100,101].
In contrast, the anti-EGFR mAbs panitumumab and nimotuzumab have shown to improve
survival outcomes in combination with chemotherapy and/or the tyrosine kinase inhibitor
erlotinib in phase 2 trials [88,92,93]. Finally, while studies with other mAbs targeting
LOXL2 and Notch2/3 receptors have not provided support for further studies in pancreatic
cancer [121,203], the results of early phase trials evaluating the efficacy of the anti-DR5
mAbs conatumumab and tigatuzumab [73,125], the anti-CD40 mAb selicrelumab [135],
and the anti-PSCA mAb AGS-1C4D4 [138] were encouraging and need to be validated in
future studies.
Of the antibody-drug conjugates tested in clinical trials in pancreatic cancer patients,
none of them showed significant clinical activity, including the anti-SLC44A4 antibody-
drug conjugate ASG-5ME [133], the anti-guanylyl cyclase C antibody-drug conjugate
TAK-264 [132], the anti-MUC16 antibody-drug conjugate DMUC5754A [204], and the anti-
mucin antibody-drug conjugate 90Y-clivatuzumab tetraxetan based on an interim analysis
of a phase 3 trial (NCT01956812). Early trials have also shown the potential of mAbs as
diagnostic tools in pancreatic cancer. For instance, the use of an anti-CEA antibody as
a fluorescent-labelled agent for intraoperative direct visualisation of tumours [205], and
the use of the anti-CA19-9 mAb HuMab-5B1 (MVT-2163) as imaging probe, which allows
visualisation of primary and metastatic tumours by immuno-PET [129]. Further clinical
studies are currently underway (NCT03801915, NCT03118349 and NCT02672917).
Monoclonal antibodies bind with high affinity and specificity to their target antigens
and these properties have been exploited for their use as theranostics, whereby tumours
are identified by radiolabelled antibodies on imaging and subsequently treated with con-
jugates targeting the same antigen. See reviews by King et.al. and Dammes & Peer for
further detail [206,207]. Antibody-based theranostic pairs have been developed targeting
a variety of antigens including carcinoembrionic antigen (CEA) [208], tissue factor [35],
CUB domain containing protein 1 (CDCP1) [209] and Met [210]. For instance, Knutson and
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colleagues have reported the development of a theranostic monoclonal antibody specific
for CEA, conjugated to paclitaxel and a PEGylated near-infrared fluorophore (DyLight™
680-4xPEG, Thermo Fisher Scientific, #46603, Rockford, IL, USA). They demonstrated that
this theranostic mAb was able to detect BxPC-3 pancreatic tumour xenografts and inhibit
tumour growth in mouse models [208]. On the other hand, Ferreira et.al. reported the
use of labelled monoclonal antibody constructs targeting tissue factor that demonstrated
high uptake in BxPC-3 tumour xenografts in PET imaging (86Y-DTPA-ALT836) and led
to slow tumour growth in mice (90Y-DTPA-ALT836) [35]. Similarly, the novel human
antibody 4A06 (which recognises CDCP1) radiolabelled with zirconium-89 (89Zr-4A06)
was able to detect CDCP1 expression, while the therapeutic constructs of the antibody
(177Lu-4A06 and 225Ac-4A06) inhibited the growth of pancreatic subcutaneous xenograft
tumours in mice [209]. Furthermore, targeting of Met by the mAb onartuzumab labelled
with zirconium-89 (89Zr) demonstrated tumour uptake of 89Zr-DFO-onartuzumab in Met
overexpressing subcutaneous and orthotopic pancreatic tumours by immunoPET, while
the construct 177Lu-DTPA-onartuzumab induced significant tumour growth delay and im-
proved survival in treated animals. 89Zr-DFO-onartuzumab was able to predict treatment
response to 177Lu-DTPA-onartuzumab [210]. Similar theranostic approaches using small
molecule inhibitors, peptides or nanoparticles targeting integrin αvβ6 [211], fibroblast acti-
vation protein [212,213], GPC1 [214] and IGF1 receptor [215] have also been investigated in
mouse models of pancreatic cancer,
Most of the currently ongoing clinical trials for pancreatic cancer treatment are evaluat-
ing anti-PD1 antibodies in combination with cytotoxic drugs, other mAbs or antibody-drug
conjugates, cancer vaccines or PARP inhibitors (Table 6). While pembrolizumab has shown
some evidence of activity in phase 2 trials in combination with chemotherapy [110], or a
CXCR4 antagonist plus chemotherapy [111], the combination of nivolumab plus chemother-
apy has shown disappointing results in a phase 1 trial [112]. Interestingly, the combination
of immune checkpoint inhibitors with GM-CSF cell-based vaccines and the oncolytic virus
pelareorep has shown promising results in early phase trials [105,109], and subsequent
studies evaluating this approach are underway (NCT03723915 and NCT03767582, Table 6).
The lack of reliable predictive biomarkers and companion diagnostic tests to identify
patients who are more likely to benefit from this form of therapy, and the development of
intrinsic or acquired resistance to mAb-based drugs are some of the factors contributing to
the poor response to therapy with not only antibody-based agents but also other forms of
therapy. In addition, other factors might impact the efficacy of therapeutic antibodies such
as impaired tumour penetration and heterogenous distribution in tumours [216]. In an at-
tempt to overcome these, strategies such as smaller antibody fragments (e.g., Fab fragments,
single-chain variable fragments and single-domain antibodies, mini-bodies and nanobod-
ies) have been investigated, although they pose unique challenges due to higher clearance
rates and significantly shorter half-lives than full-size antibodies [216]. On the other hand,
the smaller size antibody fragments are ideal for use in cancer imaging [217,218].
In summary, at present, no antibody-based drugs have yet been approved for the treat-
ment of patients with pancreatic cancer. However, we believe that the results of ongoing
clinical trials with antibody-based products, the discovery of other cell surface antigens
with high levels of expression at different stages of the disease, a better understanding of
the complex biology of pancreatic cancer, its microenvironment, the immune system and
the mechanisms of resistance, together with technological advances in the development of
various forms of antibody-based agents (e.g., bispecific/multi-specific, antibody fragments
such as mini-bodies and nanobodies, radiolabelled antibodies, antibody-drug conjugates)
would lead to the approval of monoclonal antibody-based products when used alone or in
combination with other therapeutic interventions in patients with pancreatic cancer in the
near future.
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